The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.

Methods and systems are provided for a stem cell organ device including an array of alternating stem cell channels and fluid channels. In one example, a method may include loading a stem cell channel with stem cells and flowing blood through a fluid channel in order to allow an exchange of molecules between the stem cells and the blood.

A detoxification method for treating sepsis, microbial infections, and other inflammatory conditions includes the steps of inducing flow of patient blood through a blood treatment device consisting of a bioreactor inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) and extracellular adenosine triphosphate (ATP) contained within patient blood can be irreversibly detoxified by passage of patient blood over a bioreactor surface having attached or immobilized alkaline phosphatase enzymes and acyloxyacyl hydrolase enzyme, with the bioreactor being contained within the blood treatment device. The method uses continuous treatment of a patient's blood to convert LPS and extracellular ATP in blood into inhibitors of inflammation in vivo without adding any chemicals to the bloodstream of the patient.

A blood treatment method includes the steps of inducing flow of a patient's blood through a blood treatment device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic deoxyribonucleic acid (DNA) contained within patient blood is destroyed by passing a patient's blood over a bioreactor surface having attached or immobilized deoxyribonuclease 1 (DNase 1) enzyme. The blood treatment device which consists of a bioreactor containing immobilized DNase 1, enables continuous treatment of a patient's blood and increases the effective concentration of DNase 1 in a patient's bloodstream to convert metastasizing cancer DNA in blood into non-oncogenic nucleotide fragments in vivo without adding any chemicals to the blood of the patient.

A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.

Provided is an extracorporeal filtration and detoxification system and method generally including separating ultrafiltrate from cellular components of blood, treating the ultrafiltrate independently of the cellular components in a recirculation circuit, recombining treated ultrafiltrate and the cellular components, and returning whole blood to the patient.

An EBDLR system includes a multi-layered bio purifier having a plurality of layers. Each layer includes a membrane, a first type of cells on a first side of the membrane in a first channel, and a second type of cells on a second side of the membrane in a second channel. The EBDLR includes a plasma separator to receive blood from a subject and separate a plasma component from the blood, a first reservoir to collect the plasma component, and a second pump to move the plasma component from the first reservoir to the multi-layered bio purifier. The multi-layered bio purifier distributes the plasma component into the first and second channels of each layer to purify the plasma component. The EBDLR includes a second reservoir to collect the purified plasma component and a third pump to infuse the purified plasma component from the second reservoir into the subject.

A bioreactor has a cover, a container body, a sealing portion, a driving portion and a liquid guide portion. A ventilation structure and a bacteria-retaining sealing breathable structure provided in the cover, a cleaning liquid inlet portion penetrates the bottom of the driving portion, and a liquid inlet portion and a liquid outlet portion of the liquid guide portion are arranged penetrating a sidewall of the container body. The driving portion drives, by means of elastic deformation, a liquid to be replaced or a cleaning liquid to move up and down, such that the liquid to be replaced can enter the container body only through a gas-liquid channel, so as to subsequently prevent damage to hepatic cells due to a carrier bearing a shearing force, and enable the liquid to be replaced to gain full contact with the carrier. Further provided is a bioreaction system.

Disclosed are apparatus and methods for blood and other biological fluid purification using a membrane with cell containing vascular channel systems and filtration channel systems. Also disclosed are methods of making the apparatus as well as methods of making membranes.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.